Market Place
Sourcing Support
Neurosense Announces Pricing Of Insider-Led PIPE Financing
28 Apr 2026 //
FIRSTWORD PHARMA
NeuroSense Present PrimeC Data to Be Presented at AD/PD Conf
18 Mar 2026 //
PR NEWSWIRE
Neurosense To Host Investor Webinar On December 8, 2025
03 Nov 2025 //
PR NEWSWIRE
NeuroSense Reports Ph2b Data for ALS Drug PrimeC
09 Apr 2025 //
PR NEWSWIRE
NeuroSense Therapeutics Reports 2024 Financial Results & Updates
07 Apr 2025 //
PR NEWSWIRE
NeuroSense Therapeutics Progresses ALS Drug for Canadian Market
20 Mar 2025 //
BUSINESSWIRE
NeuroSense`s ALS Trial Shows Improved Survival And Slowed Progression
09 Jul 2024 //
PR NEWSWIRE
NeuroSense Reports Positive 12-Month PARADIGM Study Results For PrimeC
01 Jul 2024 //
PR NEWSWIRE
NeuroSense Management Provides Corporate Update And Q1 2024 Financial Results
24 Jun 2024 //
PR NEWSWIRE
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
21 Jun 2024 //
PR NEWSWIRE
NeuroSense Partners With PhaseV For Optimized ALS Phase 3 Trial
14 May 2024 //
PR NEWSWIRE
NeuroSense Positive ALS Progression Data From PARADIGM
07 May 2024 //
PR NEWSWIRE
NeuroSense Announces First Quarter 2024 Business Update
02 May 2024 //
PR NEWSWIRE
NeuroSense, Genetika+ Precision Medicine Alzheimer`s Collaboration
22 Apr 2024 //
PR NEWSWIRE
NeuroSense Presenting PARADIGM Data At AAN 2024
12 Apr 2024 //
PR NEWSWIRE
NeuroSense Pricing $4.5M Offering and Private Placement
10 Apr 2024 //
PR NEWSWIRE
Lonza, NeuroSense Enter Alliance for ALS Candidate
09 Apr 2024 //
CONTRACTPHARMA
NeuroSense Announces Year End 2023 Financial Results
05 Apr 2024 //
PR NEWSWIRE
NeuroSense Reports Positive Results from its ALS Phase 2b PARADIGM Trial
21 Feb 2024 //
PR NEWSWIRE
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
07 Feb 2024 //
PR NEWSWIRE
NeuroSense`s Phase 2b ALS Trial Achieves Clinical Efficacy Endpoints
05 Dec 2023 //
PR NEWSWIRE
NeuroSense to Report Phase 2b ALS Topline Primary Safety Endpoints
04 Dec 2023 //
PR NEWSWIRE
NeuroSense Announces Third Quarter 2023 Financial Results
28 Nov 2023 //
PR NEWSWIRE
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC
13 Nov 2023 //
PR NEWSWIRE
NeuroSense Completes Dosing of Last Patient in Phase 2b ALS Trial
06 Nov 2023 //
PR NEWSWIRE
NeuroSense Therapeutics to Participate in BIO-Europe Fall
01 Nov 2023 //
PR NEWSWIRE
NeuroSense`s PrimeC Demonstrates Outstanding Effect on ALS Survival
04 Oct 2023 //
PR NEWSWIRE
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
19 Sep 2023 //
PR NEWSWIRE
NeuroSense to Participate in Upcoming ALS Conferences
14 Sep 2023 //
PR NEWSWIRE
NeuroSense Announces Second Quarter 2023 Financial Results
16 Aug 2023 //
PR NEWSWIRE
NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
17 Jul 2023 //
PR NEWSWIRE
NeuroSense to Participate in Upcoming ALS Conferences
11 Jul 2023 //
PR NEWSWIRE
NeuroSense CEO Provides Q2 2023 Update
06 Jul 2023 //
PR NEWSWIRE
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering
22 Jun 2023 //
PR NEWSWIRE
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
15 May 2023 //
PR NEWSWIRE
NeuroSense makes key progress in Phase II ALS trial
15 May 2023 //
CLINICAL TRIALS ARENA
NeuroSense reports encouraging preliminary results from PD study
02 May 2023 //
CLINICAL TRIALS ARENA
NeuroSense to Present at the ALS and Alzheimer`s Disease at AD/PD 2023 Advances
23 Mar 2023 //
PR NEWSWIRE
NeuroSense Announces Year End 2022 Financial Results & Provides Business Update
22 Mar 2023 //
PR NEWSWIRE
NeuroSense Therapeutics to Participate in BIO-Europe Spring
16 Mar 2023 //
PR NEWSWIRE
NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
13 Feb 2023 //
PR NEWSWIRE
NeuroSense and QuantalX Collaborate for Treatment of Neurodegenerative Diseases
09 Feb 2023 //
PR NEWSWIRE
NeuroSense Receives Approval in Germany to Enroll Patients in Phase 2b ALS Trial
08 Feb 2023 //
PR NEWSWIRE
NeuroSense Announces Third Quarter 2022 Financial Results
01 Dec 2022 //
PRNEWSWIRE
NeuroSense Receives Regulatory Approval for its Phase 2b Trial in ALS
16 Nov 2022 //
PRNEWSWIRE
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study
15 Nov 2022 //
PRNEWSWIRE
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
27 Oct 2022 //
PRNEWSWIRE
NeuroSense Provides CEO`s Q3 Update & Nasdaq Opening Bell Ceremony Remarks Video
18 Oct 2022 //
PRNEWSWIRE
NeuroSense to Ring Nasdaq Opening Bell & Host The ALS Combination Therapy Summit
12 Oct 2022 //
PRNEWSWIRE
NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results
28 Sep 2022 //
PRNEWSWIRE
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
21 Sep 2022 //
PRNEWSWIRE
NeuroSense Announces PrimeC Toxicology Data of PIIb PARADIGM ALS Trial
20 Sep 2022 //
PRNEWSWIRE
NeuroSense Publishes PIIa ALS Study in Amyotrophic Lateral Sclerosis
19 Sep 2022 //
PRNEWSWIRE
NeuroSense and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers
28 Jul 2022 //
PRNEWSWIRE
NeuroSense Tx Reports Positive Results from Stage III ALS Biomarker Study
27 Jun 2022 //
PRNEWSWIRE
NeuroSense CEO to be Panelist at Maxim Group`s Innovations in ALS
22 Jun 2022 //
PRNEWSWIRE
NeuroSense Enrolls 1st Patient in Phase IIb ALS Trial for PrimeC
01 Jun 2022 //
PRNEWSWIRE
NeuroSense Announces First Quarter 2022 Financial Results
31 May 2022 //
PRNEWSWIRE
NeuroSense to Present at the ALS Drug Development Summit in Boston
23 May 2022 //
PRNEWSWIRE
NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC
06 Apr 2022 //
PRNEWSWIRE
